AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights:
- Independent study validates the Parsortix system for HER2-positive breast cancer testing.
- HER2 status shifts identified in circulating tumour cells (CTCs), offering new treatment options.
- Potential to extend HER2 antibody-drug conjugates to over 60% of previously excluded patients.
ANGLE PLC (LSE:AGL, OTCQX:ANPCY) has unveiled significant independent findings from a study conducted by Weill Cornell Medicine, presented at the San Antonio Breast Cancer Symposium. The study showcased the efficacy of ANGLE’s Parsortix-based HER2 workflow, a novel approach in testing and treatment stratification for metastatic breast cancer patients.
Study Highlights New Potential for HER2 Testing
The research involved 16 patients with metastatic breast cancer and underscored the ability of the Parsortix system to identify HER2-positive circulating tumour cells (CTCs). This capability was demonstrated even in cases where conventional tissue biopsies were HER2-negative, highlighting the potential of minimally invasive liquid biopsies in enhancing diagnostic precision.
HER2, a protein influencing cancer cell growth, is a critical biomarker in breast cancer treatment. Accurate HER2 assessment is pivotal for determining the suitability of targeted therapies like antibody-drug conjugates. ANGLE’s technology offers a promising alternative to traditional methods, providing real-time insights into HER2 status.
Broadening Access to Targeted Treatments
The findings suggest that ANGLE’s Parsortix system could significantly expand access to HER2 antibody-drug conjugates. Currently, over 60% of breast cancer patients are excluded from such therapies based on tissue biopsy results. The ability to detect HER2-positive CTCs offers hope for these patients, potentially opening new avenues for treatment.
Karen Miller, ANGLE’s Chief Scientific Officer, noted the importance of these developments:
“HER2 status is known to change in up to 38% of breast cancer patients. Real-time quantitative HER2 assessment is crucial for effective treatment, patient stratification for clinical trials, and understanding dynamic HER2 changes that may correlate with therapeutic response.”
Independent Validation Strengthens ANGLE’s Position
The independent validation from Weill Cornell Medicine aligns with ANGLE’s own findings from its HER2 assay development program. This additional endorsement strengthens the credibility of the Parsortix system and underscores its utility in advancing precision medicine.
Implications for the Future
The ability to dynamically assess HER2 status through liquid biopsies presents a transformative step in breast cancer care. By enabling real-time monitoring and broadening treatment options, ANGLE’s Parsortix system stands at the forefront of innovation in oncology diagnostics.
With further clinical adoption, this technology could pave the way for more personalized and effective cancer treatments, marking a significant milestone in the fight against breast cancer.
